Potentially Resectable Hepatocellular Carcinoma
3 clinical trials · Condition
◉ Watch Potentially Resectable Hepatocellular Carcinoma
| Record | Firm | Date |
|---|---|---|
| Study on the Combined Treatment of Hepatocellular Carcinoma With Envafolimab, Suvemcitug and HAIC Conversion (NCT07738055) | Tianjin Medical University Cancer Institute and Hospital | 2026-07-31 |
| Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC) (NCT06796803) | Shanghai Zhongshan Hospital | 2025-02-20 |
| A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma (NCT06143579) | Sun Yat-sen University | 2023-12-15 |
Track Potentially Resectable Hepatocellular Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.